methyl (1R,3R)-3-aminocyclohexane-1-carboxylate hydrochloride | 1821656-07-8

• 分子结构分类: 有机化合物
• 英文名称: methyl (1R,3R)-3-aminocyclohexane-1-carboxylate hydrochloride
• 英文别名: methyl (1R,3R)-3-aminocyclohexanecarboxylate hydrochloride；trans-Methyl-3-aminocyclohexanecarboxylate hydrochloride；methyl (1R,3R)-3-aminocyclohexane-1-carboxylate;hydrochloride
• CAS: 1821656-07-8
• 化学式: C₈H₁₅NO₂*ClH
• 分子量: 193.674
• InChiKey: OOFXENVWECZJBF-ZJLYAJKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (1R,3R)-3-aminocyclohexane-1-carboxylate hydrochloride 在 水 、 碳酸氢钠 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 生成 (1R,3R)-3-(benzyloxycarbonylamino)cyclohexanecarboxylic acid
  参考文献：
  名称：

  [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES

  摘要：

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.

  公开号：

  WO2023110936A1
• 作为产物：
  描述：

  (R)-3-环己烯甲酸 在 盐酸 、 偶氮二甲酸二异丙酯 、 palladium 10% on activated carbon 、 氢气 、 碘 、 碳酸氢钠 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 、 potassium iodide 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 25.5h， 生成 methyl (1R,3R)-3-aminocyclohexane-1-carboxylate hydrochloride
  参考文献：
  名称：

  [EN] REVERSIBLE MACROCYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE RÉVERSIBLES MACROCYCLIQUES

  摘要：

  The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicament, in particular for the treatment specific kinase mediated disorders, such as cancer.

  公开号：

  WO2023110936A1

文献信息

• [EN] TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS<br/>[FR] COMPOSITIONS DE TÉTRAHYDROIMIDAZO QUINOLÉINE UTILISÉES EN TANT QU'INHIBITEURS DE CBP/P300
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2019055877A1

  公开（公告）日：2019-03-21

  The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

  本公开内容涉及CBP/p300家族溴结构域的抑制剂。这些化合物可用于治疗与CBP/p300家族溴结构域抑制相关疾病或障碍。例如，本公开内容涉及用于抑制CBP/p300家族溴结构域的化合物和组合物，治疗、预防或改善与CBP/p300家族溴结构域抑制相关的疾病或障碍的方法，以及这些化合物的合成方法。
• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2016058544A1

  公开（公告）日：2016-04-21

  The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了式（I）的新化合物及其药学上可接受的盐、溶剂化合物、水合物、互变异构体、立体异构体、同位素标记衍生物及其组合物。还提供了涉及这些化合物或组合物用于治疗或预防增生性疾病（例如，癌症（例如，白血病、黑色素瘤、多发性骨髓瘤）、良性肿瘤、血管生成、炎症性疾病、自身炎症性疾病和自身免疫性疾病）的方法和试剂盒。使用本发明的化合物或组合物治疗患有增生性疾病的受试者可能抑制细胞周期依赖性激酶（例如，CDK7）的异常活性，从而诱导受试者的细胞凋亡和/或抑制转录。
• BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS
  申请人：FORMA Therapeutics, Inc.

  公开号：US20220088005A1

  公开（公告）日：2022-03-24

  Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed. In some methods, the AR-positive forms of cancer may be breast cancer, including triple negative forms, hormone receptor positive forms, and HER2-positive forms. In other methods, the AR-positive forms of cancer may be prostate cancer, including metastatic castration resistant prostate cancer. In some embodiments, methods of treating prostate cancer comprise the step of administering to a patient in need thereof the compound (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.

  本文披露了使用CREB结合蛋白溴域抑制剂治疗某些雄激素受体阳性的癌症的方法。在某些方法中，AR阳性的癌症可能是乳腺癌，包括三阴性、激素受体阳性和HER2阳性形式。在其他方法中，AR阳性的癌症可能是前列腺癌，包括转移后的去势抵抗性前列腺癌。在某些实施例中，治疗前列腺癌的方法包括向需要的患者施用化合物（1R，3R）-3-[(7S)-2-[(R)-(5-氟-2-甲氧基苯基)(羟基)甲基]-6-(甲氧羰基)-7-甲基-3H，6H，7H，8H，9H-咪唑[4，5-f]喹啉-3-基]环己烷-1-羧酸或其药学上可接受的盐。
• [EN] COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE COMPOSÉS PYRIMIDINE ET PYRIDINE AYANT UNE ACTIVITÉ INHIBITRICE DE BTK
  申请人：MERCK PATENT GMBH

  公开号：WO2012170976A2

  公开（公告）日：2012-12-13

  The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

  本发明提供了根据公式(I)、公式(II)、公式(III)、公式(IV)和公式(V)的新型嘧啶和吡啶化合物，以及它们的制备和用于治疗高增殖性疾病，包括但不限于癌症、狼疮、过敏性疾病、Sjogren病和类风湿性关节炎。在优选实施例中，本发明描述了不可逆激酶抑制剂，包括但不限于布鲁顿酪氨酸激酶抑制剂。
• Isophtalic acid derivatives
  申请人：Harter Michael

  公开号：US20060154912A1

  公开（公告）日：2006-07-13

  The present invention relates to isophthalic acid derivatives, to a process for their preparation and to their use for producing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular of cardiovascular disorders.

  本发明涉及苯二甲酸衍生物，其制备方法以及它们用于制造用于治疗和/或预防人类和动物疾病，特别是心血管疾病的药物的用途。